Importantly, day 14-delayed ruxolitinib addition did not inhibit TSLPRCART expansion or human IFN-γ levels in murine plasma at subsequent timepoints when compared to TSLPRCART alone, which contrasted with observed suppression of T cell functionality with earlier ruxolitinib addition (Fig. 6E, F) and was consistent with results in Ph-like ALL models. Here, IFNG is linked to acute lymphoblastic leukemia.